Introduction
Vascular endothelial growth factor (VEGF) is one of the most important growth factors involved in vasculogenesis and angiogenesis. Normally, VEGF is produced by cells in close proximity to endothelial cells (such as vascular smooth muscle cells) and the expression is highly regulated by hypoxia as well as some hormones and cytokines (Ferrara, 1999; Carmeliet and Collen, 2000) . VEGF receptors (VEGFRs) are mainly expressed in endothelial cells, but have also been reported to be expressed in several nonendothelial cell types including retinal pigment epithelial cells (Guerrin et al., 1995) , Schwann cells (Sondell et al., 1999) , pancreatic duct cells (Oberg-Welsh et al., 1997) , renal mesangial cells (Takahashi et al., 1995) , macrophages and monocytes (Sawano et al., 2001 ) and platelets (Selheim et al., 2002) . By binding to VEGFRs, VEGF can protect endothelial cells from apoptosis, as well as stimulate endothelial cell proliferation, migration, and differentiation.
VEGF plays a critical role in angiogenesis induced by pathological conditions such as solid tumor growth. VEGF expression is upregulated in most human tumors examined. Many tumor-associated stromal cells also express VEGF (Ferrara, 1999) . Tumor cell expression of VEGF is critical for tumor cell-induced angiogenesis. Many tumor cells and tumor-associated vasculature express both VEGFRs and VEGF, and an autocrine/ paracrine function has been proposed (Veikkola et al., 2000) . For example, functional VEGFRs are expressed in melanoma (Liu et al., 1995) and mesothelioma (Strizzi et al., 2001 ) cell lines and exogenous VEGF stimulates cell proliferation. VEGF also stimulates human leukemic cell proliferation and migration (Dias et al., 2000) . VEGF induces MAPKs activation and cell growth in a human pancreatic cancer cell line (von Marschall et al., 2000) . In T-47D breast cancer cells, VEGF stimulates both MAPKs and PI3K (Price et al., 2001) . In M21 melanoma cells, VEGF activates integrin avb3, which is involved in cell adhesion and migration (Byzova et al., 2000) . Together, these reports highlight the importance of VEGF signaling in the biology of a variety of tumor cells in addition to its well-described role in angiogenesis.
We recently defined a VEGF-induced signaling pathway in a well-characterized bladder tumor cell line (T24) that affects the growth properties of these tumor cells (Shu et al., 2002 ). Here we extend those studies by showing that T24 cells express both VEGF and VEGFR-2 (KDR/Flk-1), which act in an autocrine loop to induce DNA synthesis. This mitogenic VEGF pathway involves the activation of PKC, sphingosine kinase (SPK), Ras-and mitogen-activated protein kinases (ERK1/2). VEGF stimulation leads to H-Ras and N-Ras activation (but not K-Ras activation) in a Ras-guanine nucleotide exchange factor (GEF) independent mechanism. Sphingosine stimulates Ras-GAP activities in vitro and this effect is blocked by excess sphingosine-1-phosphate (SPP). This suggests a novel mechanism of Ras activation that relies on Ras-GTPase activating protein (GAP) modulation rather than regulation of Ras-GEFs. PKC-and SPK-mediated VEGF stimulation of ERK1/2 was also found in prostate, breast, and neuroblastoma tumor cell lines that express VEGF receptors. Together, these results highlight a VEGF signaling pathway involving SPK that may directly affect the growth of many types of tumor.
Results

Expression of VEGF and VEGFR in bladder tumor cell lines
Most of the human tumors and tumor cell lines examined express VEGF, which plays an essential role in tumor-induced angiogenesis. Many tumors or tumorderived cell lines express functional VEGF receptors as well. The expression of VEGF in bladder tumors has been reported and VEGF levels could be used as a predictor for tumor relapse and stage progression (Brown et al., 1993; Crew et al., 1997) . We examined the expression of VEGF/VEGFRs in a human bladder carcinoma-derived cell line (T24). T24 is a human transitional urinary bladder carcinoma cell line of epithelial origin and it was used in the identification of the first human oncogene, H-ras (Taparowsky et al., 1982) . We first examined the expression of VEGF and VEGF receptors (Flk-1 and Flt-1) using the RT-PCR technique. Human umbilical vein endothelial cells (HUVECs), which express VEGF receptors (both Flk-1 and Flt-1) but very low levels of VEGF, was used for comparison. We found T24 expressed two isoforms of VEGF as well as both VEGF receptors (Figure 1a ). The sizes of the two PCR products are consistent with mRNAs encoding the VEGF-121 and VEGF-165 isoforms. The expression Flk-1 and Flt-1 was detected in both T24 cells and HUVECs. The RT-PCR conditions used here were not quantitative, therefore we examined the expression of VEGF at the protein level. We readily detected VEGF in the culture media of T24 cells using Quantikine s Human VEGF Immunoassay (R&D Systems) (Figure 1b) . We suspected that VEGF may function in an autocrine loop in T24 cells. Thus to study the effects of VEGF on T24 cells (see below), we sought a method to reduce endogenous VEGF expression such that a response to exogenous VEGF could be monitored. In these experiments, we used an anti-human VEGF antisense oligonucleotide reported to downregulate VEGF expression (Masood et al., 1997) . As shown in Figure 1b , the secretion of VEGF into the culture media in T24 cells was blocked by the antisense oligonucleotide treatment in a concentration-dependent manner. A total of 10 mm antisense oligonucleotide treatment inhibited VEGF expression by 80%, while the scrambled control oligonucleotide did not alter the expression of VEGF (Figure 1b) .
The RT-PCR conditions used above to examine VEGF receptor expression were not quantitative. Therefore to more accurately access the relative levels of VEGFRs in T24 cells and HUVECs, we carried out Western blot analysis. We examined the expression of the VEGF receptors Flk-1 and Flt-1 and two additional endothelial markers (Tie-1 and VE-Cadherin (VE-Cad)) in HUVECs and T24 cells by Western blot analysis ( Figure 1c ). As expected, HUVECs expressed all four markers. The expression level of Flk-1 was similar in T24 cells and HUVECs, while T24 cells expressed a much lower amount of VE-Cad when compared to HUVECs. T24 cells did not express Flt-1 and Tie-1 at a detectable level. We next examined the expression of these markers in 13 additional bladder tumor cell lines. Three of these cell lines expressed levels of Flk-1 comparable to that in HUVECs (5637, LD627, and 
LD692
) and five others expressed modest but detectable Flk-1 (HT1376, J82, SCaBER, TCCSUP, and UMUC-3). In contrast, none of the bladder tumor cell lines expressed Flt-1 at a significant level. Expression of Tie-1 was detected in six of the 14 bladder tumor cell lines, although the levels were significantly lower compared to that in HUVECs. Four of the 14 bladder tumor cell lines examined expressed much lower but detectable levels of VE-Cad than seen in HUVECs. The expression of Flk-1 (and the relatively high expression level when compared to other markers) in the majority of bladder tumor cell lines suggest that this receptor may be functional. The upregulation of Flk-1 could provide an advantage for tumor cell survival and/or proliferation under hypoxic conditions when VEGF is induced.
We examined the phosphorylation state of the Flk-1 tyrosine kinase receptor before and after VEGF stimulation. For this experiment, T24 cells were treated under low serum conditions with anti-VEGF antisense oligonucleotides to block a potential autocrine loop. Exogenous VEGF was then added to the culture media. Cells were harversted after 0 and 5 min of VEGF stimulation. Cell extracts were prepared and subjected to immunoprecipitation with an anti-Flk-1 antibody. The immunoprecipitates were then resolved by SDS-PAGE and transferred to PVDF membranes for immunoblot analysis. Immunoblotting with anti-Flk-1 antibody revealed that similar amounts of Flk-1 (a 200 kDa protein) were present in immunoprecipitates from VEGF-treated and untreated cells (Figure 2a) . We failed to detect Flk-1 in control mock immunoprecipitates (data not shown). The immunoblot was stripped and reprobed with antiphosphotyrosine antibody. Only after VEGF treatment did we detect a 200 kDa phosphotyrosine-containing protein comigrating with Flk-1. In addition, we detected in the anti-Flk-1 immunoprecipitates a 100 kDa phosphotyrosine-containing protein before and after VEGF treatment, although considerably more of the phosphotyrosine was detected after VEGF treatment (Figure 2a ). Similar observations of a 100 kDa phosphoprotein associated with an activated Flk-1 receptor has been reported by others (Guo et al., 1995; Kroll and Waltenberger, 1997) . We failed to detect the 200 or 100 kDa phosphotyrosinecontaining proteins in immunoprecipitates using an antineuropilin antibody (data not shown). These results suggest that VEGF stimulation of T24 cells leads to activation of the Flk-1 receptor.
The Flk-1 receptor can function alone to transduce signals or in concert with a coreceptor (neuropilin). The coreceptor function of neuropilin requires the VEGF-165 isoform and does not respond to the VEGF-121 isoform (Soker et al., 1998) . We examined the ability of VEGF-121 and VEGF-165 to stimulate phosphorylation of ERK1/2 in HUVECs and T24 cells. Both isoforms of VEGF stimulated the phosphorylation of ERK1/2 to a similar extent in HUVECs and T24 cells (Figure 2b ). We also observed that immunoblotting of HUVEC and T24 cell extracts reveals similar amounts of neuropilin (data not shown) (see Discussion).
SU1498 is a small molecule inhibitor of the Flk-1 receptor (Strawn et al., 1996) . We examined the ability of VEGF-165 to stimulate the phosphorylation of ERK1 and 2 in the presence or absence of SU1498. T24 cells were grown overnight in low serum and in the presence of the VEGF antisense oligonucleotide that blocks VEGF expression. Then cells were stimulated with VEGF or EGF in the presence or absence of SU1498. VEGF treatment induced an increase in ERK1 and 2 phosphorylation, although that of ERK1 was consistently modest (Figure 2c ). SU1498 completely blocked the VEGF-induced increase in ERK1 and 2 phosphorylation ( Figure 2c ). EGF stimulation of T24 cells resulted in activation of ERK1 and 2 and this was insensitive to SU1498. These results demonstrate that VEGF stimulates phosphorylation of Flk-1. T24 cells were serumstarved overnight then stimulated with 50 ng/ml VEGF for 0 or 5 min. Cell extracts were subject to immunoprecipitation with antiFlk-1 antibody. The levels of phosphotyrosine and total Flk-1 in immunoprecipitates were determined by Western blot analysis with specific antibodies. (b) VEGF-121 and VEGF-165 stimulation of ERK. HUVEC or T24 cells were serum-starved overnight, then stimulated with 50 ng/ml VEGF-121 or VEGF-165 for 20 min. The levels of phospho-ERK1/2 and total ERK1/2 in cell extracts were determined by Western blot analysis with specific antibodies. (c) SU1498 inhibits VEGF stimulation but not EGF stimulation of ERK. T24 cells were serum-starved overnight then stimulated with 50 ng/ml VEGF for 20 min or 10 ng/ml EGF for 10 min. Where indicated, cells were preincubated with Flk-1 inhibitor SU1498 (5 mg/ml) for 30 min. The levels of phospho-ERK1/2 and total ERK1/2 in T24 cell extracts were determined by Western blot with specific antibodies. All experiments in this figure were repeated at least twice with similar results VEGF receptor signaling in bladder tumors W Wu et al SU1498 can block VEGF but not EGF activation of ERKs. The findings suggest that VEGF stimulation of these MAP kinases in T24 cells is mediated by the Flk-1 receptor.
An autocrine loop in T24 cells stimulates DNA synthesis
The expression of VEGF and one of its receptors in T24 cells is clearly suggestive of an autocrine loop that could affect signaling that regulates the proliferative capacity of these cells. We therefore monitored DNA synthesis under conditions where serum was low and synthesis of VEGF could be controlled. In Figure 1b , we demonstrate that anti-VEGF antisense oligonucleotide can block VEGF expression in T24 cells. We therefore tested whether downregulation of endogenous VEGF with anti-VEGF antisense oligonucleotide could block DNA synthesis in T24 cells. For this we cultured T24 cells in suboptimal serum conditions in the presence of the anti-VEGF antisense oligonucleotide or scrambled control oligonucleotides and monitored DNA synthesis by measuring 
VEGF stimulation of small GTPases of the Ras and Rac families
Tyrosine kinase growth factor receptors generally activate both the Ras and Rac family of GTPases. Therefore, we examined whether VEGF stimulation of T24 cells results in accumulation of the GTP-bound form (active form) of Rac GTPases. GTP-bound forms of Rac and CDC42 from total cell extracts were precipitated with an immobilized domain of PAK-1 (that specifically interacts with GTP-bound but not GDP-bound forms of these GTPases) and the levels of Rac and CDC42 were detected by Western blot analysis. As shown in Figure 4a , VEGF treatment of quiescent T24 cells resulted in the time-dependent accumulation of the Rac-GTP and CDC42-GTP.
We previously found that Ras-GTP accumulates in response to VEGF treatment of T24 cells and this is Cells were first serum-starved overnight, then stimulated with 50 ng/ml VEGF for the indicated times. The Rac-GTP and CDC42-GTP in cell extracts were precipitated by immobilized PAK-1 PBD and detected by Western blot analysis. (b) VEGF stimulation of H-, N-Ras but not K-Ras in T24 cells in a PKC-and SPK-dependent manner. T24 cells were serum-starved overnight then stimulated with 50 ng/ml VEGF for 15 min. Where indicated, cells were preincubated with PKC inhibitors (Go¨6967 and Go¨6983, 200 nm each) or SPK inhibitor (DMS, 10 mm) for 30 min. Ras-GTP was precipitated with agarose-conjugated Raf-1 Ras-binding domain and separated by 15% SDS-PAGE. The level of precipitated H-, N-, and K-Ras was determined by Western blot analysis with specific antibodies. The membrane was first probed with antibodies to H-Ras and then stripped and reprobed sequentially with N-Ras antibody and K-Ras antibody. Finally, as a control, the membrane was stripped again and reprobed with the anti-H-Ras antibody. The final results were similar to those shown in the figure for H-Ras. All experiments in this figure were repeated at least twice with similar results
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W Wu et al dependent on PKC and SPK activities (Shu et al., 2002) . However, we did not determine which members of the Ras family were involved. We therefore monitored the accumulation of H-Ras-GTP, N-Ras-GTP and K-Ras-GTP in response to VEGF stimulation in T24 cells using antibodies specific for the individual Ras proteins. An immobilized Ras-binding domain of the Raf kinase was used to precipitate all species of Ras-GTP in cell extracts prepared from T24 cells with or without VEGF treatment. Subsequent Western blot analysis using H-, K-, or N-Ras specific antibodies then allowed evaluation of accumulation of GTP-bound versions of each of the Ras proteins in response to VEGF. In these experiments, we observed a dramatic increase in N-Ras-GTP and a lesser induction of H-Ras-GTP after VEGF treatment (Figure 4b) . The uninduced basal level of H-Ras-GTP was greater than N-Ras-GTP (Figure 4b ). K-Ras-GTP was not detected in T24 cells with or without VEGF treatment. We further tested whether PKC and SPK are involved in VEGF stimulation of Ras by using PKC inhibitors (Go¨6967 and Go¨6983) (Martiny-Baron et al., 1993) and the SPK inhibitor dimethylsphingosine (DMS) (Edsall et al., 1998) . Activation of H-, K-, and N-Ras was monitored in the presence of inhibitors of SPK or PKC. We observed complete inhibition of the VEGF stimulation of H-Ras-GTP and N-Ras-GTP accumulation (Figure 4b ) with both types of inhibitors. We conclude that VEGF stimulation of the Ras pathway in T24 cells requires the involvement of PKC and SPK and that both H-Ras and N-Ras are probably actively involved in this process.
Regulation of Ras-GAP activity by sphingolipids
Previously, we reported that VEGF-induced signaling events in T24 cells were unaffected by the dominant interfering Ras mutant (Ras-N17), while that induced by EGF was completely blocked by Ras-N17. Ras-N17 is known to sequester endogenous Ras-GEFs in an inactive complex. Thus, we concluded that in contrast to EGF signaling that is known to require the Ras-GEF, Sos, VEGF signaling to Ras occurs independent of RasGEFs. Interestingly, activation of Ras induced by the PKC activator, PMA, is reported to occur in the presence of a dominant interfering Ras-N17 mutant (Marais et al., 1998) . Thus receptor-mediated events that activate Ras via a PKC-dependent mechanism may do so independent of Ras-GEFs. Since both Ras-GEFs and Ras-GAPs regulate cellular Ras-GTP levels, we propose that Ras-GAPs might contribute to the VEGF stimulation of Ras in T24 cells. Several studies showed that the activity of Ras-GAPs (p120GAP and NF1) could be regulated in vitro by a variety of lipids including free fatty acids, phosphatidic acids, arachidonic acids and prostaglandins, although the in vivo relevance was unclear (Bollag and McCormick, 1991; Golubic et al., 1991; Han et al., 1991) . We predicted that VEGF stimulation of SPK, which shifted the balance of sphingolipids from sphingosine to SPP, might downregulate the activity of Ras-GAPs and induce Ras-GTP accumulation.
We therefore examined the effect of sphingolipids on Ras-GAP activities in an in vitro GAP assay, which measured the ability of Ras-GAPs to stimulate the hydrolysis of Ras-bound [g-32 P]GTP. We immunoprecipitated p120GAP and NF1 from T24 cells and preincubated them with various sphingolipids, then measured their GAP activity. As shown in Figure 5a , both p120GAP and NF1 stimulated the GTPase activity of H-Ras in vitro. Preincubation of p120GAP and NF1 with 10 mm sphingosine, but not SPP, ceramide or ceramide-1-phosphate, further stimulated the GTPase activity of H-Ras (Figure 5a ). In the absence of Ras GAPs, sphingosine had no effect on the Ras GTPase activity (data not shown). The GTPase activity of Ras-V12, which did not respond to Ras-GAPs regulation, was unaffected by sphingosine (data not shown). These data suggested that sphingosine can directly stimulate the GAP activity of both p120GAP and NF1.
Sphingosine stimulation of the GAP activity of p120GAP and NF1 was concentration dependent and 100 nm sphingosine resulted in approximately half maximal stimulation (Figure 5b ). We also found that sphingosine activation of GAP activity was completely reversed by the presence of excess SPP (Figure 5c ). This suggested that sphingosine and SPP might compete for a single binding site to regulate Ras-GAPs. Although the exact mechanism remains to be elucidated, these data suggested a pathway for VEGF stimulation of MAPKs as follows: stimulation of SPK by VEGF results in conversion of sphingosine to SPP and decreases the activity of Ras-GAPs, which results in the Ras-GTP accumulation in a Ras-GEF-independent manner. Ras-GTP then stimulates Raf kinase, which leads to the activation of MAP kinases.
A VEGF, PKC and SPK pathway functions in various tumor types
The analysis described here and in our earlier study (Shu et al., 2002 ) define a VEGF-induced signaling pathway involving the sequential activation of Flk-1, PKC, SPK, Ras, Raf, and ERK1/2 that leads to stimulation of DNA synthesis. To determine whether a similar signaling pathway is operational in other types of solid tumors, we analysed cell lines from a breast carcinoma (T-47D), prostate carcinoma (DU-145), and a neuroblastoma (SK-N-SH) reported to express VEGF receptors (Ferrer et al., 1999; Meister et al., 1999; Price et al., 2001) . Each of these cell lines was serum-starved and then stimulated with VEGF in the presence or absence of PKC and SPK inhibitors. As we had reported for T24 cells (Shu et al., 2002) , each of these tumor cell lines were responsive to VEGF treatment showing a dramatic increase in levels in phosphorylated forms of ERK1/2 (Figure 6 ). In all cases, pretreatment of these cell lines with the PKC inhibitors or the SPK inhibitor resulted in a 50-90% inhibition of ERK1/2 phosphorylation ( Figure 6 ). Together, these results demonstrate that a variety of solid tumors can respond to VEGF by induction of a pathway involving VEGFRs, PKC, SPK, and the mitogen-activated protein kinases, ERK1 and 2.
Discussion
Although VEGF signaling is thought to occur primarily in endothelial cells, numerous studies have suggested that VEGF may act in an autocrine loop fashion in a variety of malignant tumor cells including melanoma (Liu et al., 1995) , mesothelioma cells (Strizzi et al., 2001) , leukemia (Dias et al., 2000) , pancreatic tumor cells (von Marschall et al., 2000) and breast cancer cells (Price et al., 2001) . Our analysis of a series of bladder tumor cell lines finds that the majority of these express a VEGF receptor. More than a third (five of 14) of the bladder tumor cell lines expressed levels of Flk-1 as high as that seen in HUVECs. Thus, it appears that a large percentage and a wide variety of human tumors have upregulated a receptor that is normally expressed in endothelial cells. The reports that most solid tumors secrete VEGF under hypoxic conditions therefore has important functional implications not only for tumorinduced angiogenesis but also for the tumor cells themselves. Since we find T24 cells express levels of Flk-1 comparable to that in HUVECs, but very little Flt-1 (Figure 1c) , we suggest that the VEGF-induced signaling described here for T24 cells reflects Flk-1 signaling. Two additional observations support our suggestion that Flk-1 receptors are functional in T24 cells. First, we show here that the Flk-1 receptor in T24 cells is phosphorylated on tyrosine in response to VEGF (Figure 2a) . Second, an inhibitor of the Flk-1 receptor (SU1498) blocks the ability of VEGF to activate ERKs in T24 cells (Figure 2c ). The Flk-1 receptor can function alone to transduce signals or in concert with a coreceptor, neuropilin (Soker et al., 1998) . The neuropilin coreceptor can contribute to VEGF-165-mediated signaling, but not that of VEGF-121 (Soker et al., 1998) . We observe the activation of ERKs in T24 cells can be observed after treatment with VEGF-121 or VEGF-165 suggesting that the neuropilin coreceptor is not essential for VEGF signaling in T24 cells. However, we do detect neuropilin in T24 cells and thus cannot rule out the possibility that this coreceptor aids in the response to VEGF-165, especially when exposed to low concentrations of VEGF-165.
It will be interesting to determine whether Flt-1 signaling is similar to that of Flk-1 in the use of SPK. The prostate tumor cell line, DU-145, has been reported to express Flt-1, but not Flk-1 (Ferrer et al., 1999) . Our analysis of this cell line shows that VEGF activation of ERK1/2 is blocked by the SPK-inhibitor, DMS. While further analysis is required, these observations suggest that Flt-1, like Flk-1, also signals to ERK1/2 via SPK. The reports that activation of Flk-1 and Flt-1 each lead to PKC activation (Podar et al., 2002) , and our observation that PKC can phosphorylate and activate SPK (Shu et al., 2002) also argue that both of these receptors may signal through SPK. Given that the two receptors lead to different phenotypic changes, it will be important to determine how signaling from these receptors differ and thereby result in distinct responses.
VEGF can alter the behavior of endothelial cells in several ways that are thought to be important for angiogenesis. VEGF activation of the endothelium also causes an upregulation and secretion of matrix metalloproteinases (MMPs) that degrade and remodel the extracellular matrix creating an environment that stimulates migration and invasive behavior of endothelial cells (Zucker et al., 1998) . VEGF stimulates endothelial cell proliferation and cell survival. The results presented here and by others suggest that VEGF secretion stimulates mitogenic signaling not only in the endothelium, but also in the tumor cell themselves. Our finding that VEGF treatment of T24 cells results in accumulation of Rac-GTP and CDC42-GTP suggests that VEGF may stimulate migration of T24 cells. We are currently investigating this possibility.
A previous report found that PKC-dependent activation of Ras can occur in the presence of Ras-N17 that sequesters and inactivates endogenous Ras-GEFs (Marais et al., 1998) . We found that VEGF-induced signaling, which is mediated by PKC, is also insensitive to Ras-N17 (Shu et al., 2002) . Together, these results suggest that PKC-mediated activation of Ras is not dependent on Ras-GEFs. Since PKC-mediated activation of Ras requires SPK activity, we reasoned that sphingolipids might regulate Ras-GAP activities to affect Ras activation. Consistent with this suggestion, we found that sphingosine can activate Ras-GAP activities and this activation is reversed by excess SPP. Since Ras-GAPs used in these studies were immunoprecipitated from cells, we cannot rule out the possibility that an associated protein mediates the effects of sphingolipids on Ras-GAP activity. While other lipids and fatty acids have been reported to modulate Ras-GAP activities in vitro, the required concentrations of these were significantly higher than what we found for sphingosine activation of Ras-GAPs (Bollag and McCormick, 1991; Golubic et al., 1991; Han et al., 1991) . Furthermore, the lipids previously reported to regulate Ras-GAPs had not been implicated in a signaling pathway leading to Ras activation. In contrast, the relevance of sphingosine to Ras activation is demonstrated by our previous observation that SPK inhibition completely blocks VEGF-induced activation of Ras (Shu et al., 2002) . We are currently seeking to define the molecular mechanism by which sphingolipids modulate Ras-GAP activities.
Previously, we found that VEGF stimulation of the MAPK pathway in T24 bladder carcinoma cells is mediated through the sequential involvement of protein kinase C, SPK, Ras, Raf and ERK (Shu et al., 2002) . The VEGF receptor signaling pathway is distinct from tyrosine kinase receptors such as the EGF receptor in the involvement of SPK that leads to Ras activation and in that Ras activation appears not to require a guanine nucleotide exchange factor. VEGF-induced stimulation of PKC mediates the activation of SPK. Here we demonstrate that a similar pathway is operational in a variety of tumor cell lines. We analysed a breast, prostate, and neuroblastoma tumor cell lines that express VEGF receptors and observed that VEGFinduced activation of ERK1/2 is blocked by inhibitors of PKC and SPK. Thus, we conclude that a signaling pathway similar to that we described for T24 cells may be functional in a wide variety of human tumors.
Mutational activation of the Ras oncogene is a common event in the development of human tumors and was first described for the T24 human bladder tumor (Taparowsky et al., 1982) . The mutational activation of Ras usually results in Ras proteins with dramatically impaired GTPases activities resulting in an increase in GTP-bound Ras in vivo. While such mutations provide a proliferative advantage to the tumor cells, they do not necessarily induce constitutive proliferation, but rather sensitize tumor cells to external mitogenic stimuli. Like most tumor cell lines, T24 cells are induced to quiescence by serum starvation, and respond to external growth stimuli. Analysis of H-, K-, and N-Ras levels in quiescent and VEGF-stimulated T24 cells clearly demonstrate a VEGF-induced accumulation of Ras-GTP. We observe that the uninduced basal levels of H-Ras-GTP are greater than that of NRas-GTP. The higher basal level of H-Ras-GTP likely reflects that one allele of H-Ras encodes a protein with a defective GTPase activity. However, a significant increase in the H-Ras-GTP levels is observed after VEGF treatment. In addition, we observe a dramatic accumulation of N-Ras-GTP, but not K-Ras-GTP, in response to VEGF. Thus, in serum-deprived conditions, T24 cells may have a higher than normal basal level of GTP-bound Ras because of mutational activation, but respond to VEGF with a robust accumulation of both H-and N-Ras-GTP.
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On a technical note, we first received the T24 cell line from a laboratory that suggested this cell line was the Kaposi's sarcoma cell line, KS Y-1. During the course of our studies, the American Type Culture Collection (ATCC) sent out a warning that the KS Y-1 cell line they were distributing was indeed the T24 bladder tumor cell line. We compared the expression of genetic polymorphic markers on the cell line we had obtained with that of an authentic T24 cell line. The result demonstrated that the cell line we obtained was genetically identical to the T24 cell line (Table 1) . This observation highlights the potential problems with the KS Y-1 cell line that has been distributed to many laboratories.
Materials and methods
Materials
VEGF-121 and VEGF-165 were purchased from R&D Systems. N,N-DMS were purchased from Sigma. PKC inhibitors Go¨6967 and Go¨6983 were purchased from CalBiochem. . Cell culture media were purchased from Invitrogen. Antibody to Flt-1, neuropilin, Tie-1, E-Cad, NRP-1, H-Ras, N-Ras, K-Ras, p120GAP, NF1 were purchased from Santa Cruz Biotechnology. Antibody to Flk-1 and antiphosphotyrosine were purchased from Upstate Biotechnology. Antibody to ERK1/2 and phospho-ERK1/2 were purchased from Cell Signaling Technology. Secondary antibodies were purchased from Santa Cruz Biotechnology.
Cell cultures
T24 cells were maintained in RPMI 1640 with 5% FBS, 1% Pen-Strep at 371C with 5% CO 2 . Except where indicated, VEGF-165 was used for VEGF in all experiments. In some experiments, anti-hVEGF antisense oligonucleotide (5 mm) were added to the media to inhibit the endogenous VEGF synthesis. T-47D cells were maintained in RPMI 1640/10% FBS, 0.2 IU insulin/ml and 1% Pen-Strep. DU-145 and SK-N-SH cells were maintained in EMEM/10% FBS, 1% Pen-Strep. Cell culture media for other bladder tumor cell line were: RPMI 1640/10% FCS/1% Pen-Strep for 5637; DMEM/10% FCS/1% Pen-Strep for HT1376, RT4, SCaBER, UMUC-3, LD71, LD605, LD611, LD627 and LD630; MEM/10% FCS/ 1% Pen-Strep for TCCSUP and J82; KERA/10% FCS/1% Pen-Strep for LD692.
RT-PCR
Total RNA was purified from T24 cells or HUVECs with NucleoBond RNA/DNA Purification Kits (Clontech) according to the manufacturer's protocol. The first-strand cDNA was synthesized in a 20 ml reaction mixture containing 5 mg total RNA, 10 pmol oligo(dT), 4 ml 5 Â first-strand buffer, 2 ml 0.1 m DTT, 1 ml 10 mm dNTPs and 1 ml of Superscript TM II RNase HReverse Transcriptase (Invitrogen). Each PCR mixture (total volume of 100 ml) contained 5 ml of first-strand cDNA, 100 pmol of each primer, 10 ml 10 Â PCR buffer, 4 ml 5 mm dNTPs and 1 ml Taq polymerase. For VEGF, Flt-1 and Flk-1, the annealing temperature was 651C and the PCR reactions were performed for 32 cycles with 1 min for each step. For bactin, the PCR reaction was performed for 30 cycles with the annealing temperature of 601C. 
Human VEGF immunoassay
Western blot
Cell extracts (about 20 mg total protein) were separated in 8% SDS-PAGE and transferred to Immun-Blott PVDF membrane (Bio-rad). The membrane was first blocked in 5% milk for 1 h then incubated with primary antibody (0.2 mg/ml) overnight at 41C. After washing three times with TTBS (20 mm Tris, 500 mm NaCl, 0.1% Tween-20, pH 7.5), the membrane was incubated with alkaline phosphatase-conjugated secondary antibody (1 : 3000 dilution) for 1 h at room temperature. The membrane was then extensively washed with TTBS and developed with Immun-Start Chemiluminescent Protein Detection Systems (Bio-Rad). Membrane was stripped with Restoret Western blot stripping buffer (Pierce).
Immunoprecipitation
T24 cells in 100 mm dishes were serum-starved overnight and stimulated with 50 ng/ml of VEGF for 0 or 5 min. Cells were 
ERK1/2 activation assay
Cells were cultured in 60 mm dish to confluence. After serumstarvation overnight, cells were then stimulated with 50 ng/ml VEGF for 20 min. Wherever indicated, cells were preincubated with PKC inhibitors (Go¨6967 and Go¨6983, 200 nm each) or SPK inhibitor (DMS, 10 mm) for 30 min. Cells were lysed in buffer (20 mm Tris/HCl pH 7.5, 150 mm NaCl, 1% Triton X-100, 1 mm Na 3 VO 4 , 10 mm b-glycerophosphate, 50 mm NaF, 5 mm sodium pyrophosphate, 1 mm PMSF, 10 mg/ml aprotinin and leupeptin). Cell extracts (about 20 mg of total protein) were separated by 10% SDS-PAGE and the levels of phospho-ERK1/2 and total ERK1/2 detected by Western blot with specific antibodies (1 : 1000 dilution, Cell Signaling Technology).
GAP assay
T24 cells were lysed in buffer containing 20 mm HEPES pH 7.3, 1.0% NP-40, 2 mm EDTA, 2 mm DTT, 10 mm NaF, 1 mm Na 3 VO 4 , 1mm PMSF, 10 mg/ml leupeptin and pepstatin. p120GAP and NF1 were immunoprecipitated from the cell extracts and washed with 1 Â PBS/0.1% Triton and Buffer A (20 mm HEPES pH 7.3, 2 mm MgCl 2 and 2 mm DTT). GAP assay was performed as described (Bollag and McCormick, 1995) . Briefly, His-Ras was purified from E. coli and loaded with [g-32 P]GTP in a 50 ml reaction mixture containing 20 mm HEPES pH 7.3, 1 mm EDTA, 2 mm DTT, 50 nm [g-32 P]GTP and 500 nm His-Ras. After 5 min incubation at 251C, 450 ml buffer A was added to the reaction and the mixture was kept on ice for further use. In each GAP assay reaction, 20 ml p120GAP or NF1/beads complex was preincubated with the indicated sphingolipids in 40 ml buffer A for 10 min at 251C with constant rotation. Then 20 ml of Ras-GTP was added to the reaction and incubated for another 10-15 min. The reaction mixture was transferred to nitrocellulose filter and washed with excess buffer A and the remaining [g-32 P]GTP on Ras was quantitated by liquid scintillation counter. Assay was repeated at least three times with similar results. Data represent means7s.d.
Genetic identification of the T24 bladder carcinoma cell line
Despite the importance of VEGF in the development of solid tumor, signaling events activated by VEGF are not well characterized. To study VEGF signaling we obtained a Kaposi's sarcoma cell line (KS-Y1) of putative endothelial cell origin hoping this cell line might be a convenient way defining an endothelial cell VEGF signaling pathway. In the course of these studies, we learned that some KS-Y1 cell lines were indeed a well-characterized human bladder tumor cell line (T24) from which the first human oncogene was cloned. Therefore, in order to determine the true identity of the cells we were studying, we compared several genetic loci of these cells with an authentic source of T24 cells using the Applied Biosystems Amplitype AE PM+DQA1 PCR Amplification and Typing Kit. The results of this experiment demonstrated that the putative KS-Y1 cells were in fact identical to the authentic T24 bladder carcinoma cells (Table 1) . The putative KS cells were found to be genetically identical to the T24 bladder carcinoma cell line. The polymorphic genetic loci tested were low-density lipoprotein receptor (LDLR), glycophorin A (GYPA), hemoglobin G gammaglobin (HBGG), D7S8 and group-specific component (GC) using the Applied Biosystems Amplitype AE PM+DQA1 PCR Amplification and Typing Kit.
Statistical analysis
All graphs with error bars indicate means7s.d. Student's t-test was used to compare between groups. All statistical significance levels reported are two sided. P values below 0.05 are considered statistically significant.
